Cutanea Life Sciences files IPO to fund Omiganan development

Written by on September 22, 2010 in New Rosacea Treatments with 1 Comment

News today that yet another company is accessing funding to pursue research and development for a new treatment targeting the papules and pustules of rosacea.

We learnt in 2006 that Cutanea were trialing Omiganan for rosacea.

The treatment is known as a topical cationic peptide. This treatment has anti-inflammatory properties that were promising for acne. Now the developers are planning to trial it next year against rosacea.

CLS001 (omiganan pentahydrochloride) is described as “a novel cationic antimicrobial peptide in development for the treatment of inflammatory papules and pustules associated with rosacea”.

Further; “CLS001 is formulated in an aqueous based topical gel.  It is designed to provide cosmetic elegance with minimal irritation.  Cutanea believes that CLS001 will offer the following advantages: rapid onset of action, antimicrobial and anti-inflammatory activity, and non-detectable systemic absorption, thereby causing minimal adverse side effects.”

We learnt in 2007 that Cutanea had selected a once-daily dose of omiganan 2.5% for further development for the treatment of papulopustular rosacea.

Cutanea Announces Promising Phase II Results in Rosacea with Omiganan

Plans to Move Forward with Phase III

Malvern, PA. October 17, 2007

While cationic antimicrobial peptides, such as Omiganan, are well known for their antimicrobial properties, recent research has shown that they also may play a role in the inflammatory response. Omiganan, in in vitro assays, demonstrated a rapid bactericidal activity against microorganisms that colonize the skin and that may play a role in the pathogenesis of inflammatory lesions.

The news today is that Cutanea are to undergo an Initial Public Offering to raise funds, in part, to continue developing the product known as CLS-001. The plan is to launch Phase III trials in mid-2011.

Here is today’s press release.

Cutanea’s Deficit Widens As It Readies Skin Treatment

Cutanea Life Sciences Inc.’s accumulated deficit grew to $20.1 million last quarter as the developer of skin treatments prepares to bring its most advanced product candidate into late-stage clinical trials with the proceeds of a planned initial public offering.

The Malvern, Pa.-based company, which registered for an IPO last month, said in an amended prospectus last week that its accumulated losses as of June 30 widened from $19.7 million three months earlier.

Cutanea’s first product, omiganan, is being developed to treat the skin disease rosacea. The company plans to launch a Phase III trial in mid-2011. It also is developing omiganan for the treatment of atopic dermatitis and potentially other diseases.

The company plans to use the proceeds of its IPO to fund those studies as well as research and development of omiganan and a second product, chitosan, a dermal filler. It said it expects to have enough money from the IPO and available cash to last it through the first quarter of 2012.

The company expects to file a New Drug Application for its rosacea treatment with the Food and Drug Administration in 2013.

Related Articles

Read more about: New Rosacea Treatments

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. RossAcne says:

    This is great news! Thank you for sharing this.

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.